The MSG levels of miR200b-5p were significantly ↓in pSS patients, who will develop or have NHL, and strongly discriminated (p<0.0001) them from those without lymphoma or non-SS sialadenitis. Furthermore, they were reduced long before clinical onset of lymphoma, did not significantly change on transition to lymphoma and, importantly, were proved strong independent predictors of patients, who will develop NHL (p<0.0001). MiR200b-5p levels correlated negatively with ESSDAI and biopsy focus score, and positively with serum C4 levels. The gene discussed is C4A; the disease is sialadenitis.